Q1 FY27 Results Approved: Revenue Rs 343L, PAT Rs 14L vs Loss Last Year
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.4 pts less than Nifty Microcap 250 and 1.0 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Board approved unaudited Q1 FY27 results. Revenue from operations rose to Rs 343.27 lakh from Rs 315.11 lakh in Q1 FY26, up about 9 percent. Total income stood at Rs 350.12 lakh. Profit after tax turned around to Rs 13.62 lakh versus a loss of Rs 1.88 lakh in the year-ago quarter. EPS came in at Rs 0.025 against Rs (0.003) earlier. Full-year FY26 revenue was Rs 1,052 lakh with PAT of Rs 0.51 lakh. Statutory auditor Doshi Doshi and Co issued an unmodified limited review report with no qualifications.
Positive quarterly turnaround with revenue growth and a swing to profit from a year-ago loss, though absolute numbers remain small for the company.